{"id":4277,"date":"2019-11-19T19:24:57","date_gmt":"2019-11-19T18:24:57","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4277"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"vorlaeufige-pharmakokinetische-und-pharmakodynamische-daten-aus-der-topaz-phase2-studie-mit-srk-015","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/vorlaeufige-pharmakokinetische-und-pharmakodynamische-daten-aus-der-topaz-phase2-studie-mit-srk-015\/","title":{"rendered":"Vorl\u00e4ufige pharmakokinetische und pharmakodynamische Daten aus der TOPAZ Phase2 Studie mit SRK-015"},"content":{"rendered":"\n<div class=\"wp-block-group has-subtle-background-color has-background tw-shadow\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>Dosisabh\u00e4ngige Erh\u00f6hungen des latenten Myostatinspiegels im Serum nach Behandlung mit SRK-015 (2 mg \/ kg und 20 mg \/ kg Dosen) um das bis zu 100-fache best\u00e4tigen das Vorhandensein von latentem Myostatin bei Patienten mit SMA und zeigen eine robuste Zielbindung.<\/p><p>Der Anstieg des latenten Myostatinspiegels im Serum vom Ausgangswert in den ersten vier Wochen nach der Behandlung mit SRK-015 war zwischen SMA-Patienten in der TOPAZ-Studie und gesunden erwachsenen Probanden in der Phase 1-Studie vergleichbar.<\/p><cite>Quelle: <a href=\"http:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-reports-preliminary-pharmacokinetic-and\/\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"'Scholar Rock' Press Release (\u00f6ffnet in einem neuem Tab)\">&#8216;Scholar Rock&#8217; Press Release<\/a> (automat. \u00fcbersetzt, gering angepasst)<\/cite><\/blockquote>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dosisabh\u00e4ngige Erh\u00f6hungen des latenten Myostatinspiegels im Serum nach Behandlung mit SRK-015 (2 mg \/ kg und 20 mg \/ kg Dosen) um das bis zu 100-fache best\u00e4tigen das Vorhandensein von latentem Myostatin bei Patienten mit SMA und zeigen eine robuste Zielbindung. Der Anstieg des latenten Myostatinspiegels im Serum vom Ausgangswert in den ersten vier Wochen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4277","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4277"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4277\/revisions"}],"predecessor-version":[{"id":39856,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4277\/revisions\/39856"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}